<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13433">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00397540</url>
  </required_header>
  <id_info>
    <org_study_id>10-2006-001</org_study_id>
    <nct_id>NCT00397540</nct_id>
  </id_info>
  <brief_title>The Effect of Viral Load on Intrahepatic Recurrence in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC)</brief_title>
  <official_title>Prospective Cohort Study of the Effect of Serum HBV DNA Level on Intrahepatic Recurrence in Locally Treatable, HBV-related HCC Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of serum hepatitis B virus (HBV) DNA
      level on intrahepatic recurrence in locally treatable hepatocellular carcinomas (HCCs)
      related with HBV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective cohort study

      Survival

        -  Overall survival rate

        -  Disease free survival rate

      Recurrence

        -  Cumulative recurrence rate
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>1,3,5 Year-Disease Free Survival (or Recurrence Free Survival)</measure>
    <time_frame>1,3,5 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>The disease free survival is defined as the total number of surviving participants without intrahepatic recurrence of hepatocellular carcinoma for 1, 3, and 5 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1,3,5-year Overall Survival</measure>
    <time_frame>1,3,5-year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">145</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>percutaneous ethanol injection therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with hepatocellular carcinoma who will be treated with PEIT (percutaneous ethanol injection therapy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>radiofrequency thermal ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with hepatocellular carcinoma who will be treated with RFTA (radiofrequency thermal ablation)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PEIT</intervention_name>
    <description>Percutaneous Ethanol Injection Therapy</description>
    <arm_group_label>percutaneous ethanol injection therapy</arm_group_label>
    <other_name>PEI, local ablation therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RFTA</intervention_name>
    <description>Radiofrequency Thermal Ablation</description>
    <arm_group_label>radiofrequency thermal ablation</arm_group_label>
    <other_name>RFA, local ablation therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Child-Pugh Class A or B

          -  Maximal tumor size less than 5 cm

          -  No previous history of treatment for hepatocellular carcinoma

          -  Recurrent hepatocellular carcinoma located more than 2 cm from the previous cancer
             site and is found more than 1 year's gap

        Exclusion Criteria:

          -  Hepatocellular carcinoma in portal vein

          -  Hepatocellular carcinoma in hepatic vein
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Won Kim, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 18, 2015</lastchanged_date>
  <firstreceived_date>November 7, 2006</firstreceived_date>
  <firstreceived_results_date>September 22, 2009</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jung-Hwan Yoon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>HBV DNA</keyword>
  <keyword>HCC</keyword>
  <keyword>recurrence</keyword>
  <keyword>PEIT</keyword>
  <keyword>RFTA</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Percutaneous Ethanol Injection Therapy</title>
          <description>99% of ethanol injected using standard percutaneous ethanol injection therapy (PEIT) intervention technique under the guidance of ultrasonography. Each procedure usually comprises 2 to 3 sessions.</description>
        </group>
        <group group_id="P2">
          <title>RFTA</title>
          <description>high ultrasonic wave energy applied using standard radiofrequence thermal ablation (RFTA) intervention technique by incurring coagulation necrosis. Each procedure usually comprises only one session.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>short follow-up duration &lt; 12 months</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PEIT</title>
          <description>99% of ethanol injected using standard percutaneous ethanol injection therapy (PEIT) intervention technique under the guidance of ultrasonography. Each procedure usually comprises 2 to 3 sessions.</description>
        </group>
        <group group_id="B2">
          <title>RFTA</title>
          <description>high ultrasonic wave energy applied using standard radiofrequence thermal ablation (RFTA) intervention technique by incurring coagulation necrosis. Each procedure usually comprises only one session.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="60"/>
                <measurement group_id="B2" value="85"/>
                <measurement group_id="B3" value="145"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="56" lower_limit="39" upper_limit="72"/>
                <measurement group_id="B2" value="58" lower_limit="27" upper_limit="71"/>
                <measurement group_id="B3" value="56" lower_limit="27" upper_limit="72"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="11"/>
                <measurement group_id="B3" value="26"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="45"/>
                <measurement group_id="B2" value="74"/>
                <measurement group_id="B3" value="119"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Korea, Republic of</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="60"/>
                <measurement group_id="B2" value="85"/>
                <measurement group_id="B3" value="145"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Treatment modality</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="60"/>
                <measurement group_id="B2" value="85"/>
                <measurement group_id="B3" value="145"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>1,3,5 Year-Disease Free Survival (or Recurrence Free Survival)</title>
        <description>The disease free survival is defined as the total number of surviving participants without intrahepatic recurrence of hepatocellular carcinoma for 1, 3, and 5 years.</description>
        <time_frame>1,3,5 year</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT analysis</population>
        <group_list>
          <group group_id="O1">
            <title>PEIT</title>
            <description>99% of ethanol injected using standard percutaneous ethanol injection therapy (PEIT) intervention technique under the guidance of ultrasonography. Each procedure usually comprises 2 to 3 sessions.</description>
          </group>
          <group group_id="O2">
            <title>RFTA</title>
            <description>high ultrasonic wave energy applied using standard radiofrequence thermal ablation (RFTA) intervention technique by incurring coagulation necrosis. Each procedure usually comprises only one session.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="62"/>
                  <measurement group_id="O2" value="84"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>1,3,5 Year-Disease Free Survival (or Recurrence Free Survival)</title>
            <description>The disease free survival is defined as the total number of surviving participants without intrahepatic recurrence of hepatocellular carcinoma for 1, 3, and 5 years.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>1 year-disease free survival</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>3 year-disease free survival</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="34"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>5 year-disease free survival</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="37"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1,3,5-year Overall Survival</title>
        <time_frame>1,3,5-year</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>05/2018</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Percutaneous Ethanol Injection Therapy</title>
          <description>99% of ethanol injected using standard percutaneous ethanol injection therapy (PEIT) intervention technique under the guidance of ultrasonography. Each procedure usually comprises 2 to 3 sessions.</description>
        </group>
        <group group_id="E2">
          <title>RFTA</title>
          <description>high ultrasonic wave energy applied using standard radiofrequence thermal ablation (RFTA) intervention technique by incurring coagulation necrosis. Each procedure usually comprises only one session.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Won Kim</name_or_title>
      <organization>Seoul National University Hospital Boramae Medical Center</organization>
      <phone>82 2 870 2233</phone>
      <email>wonshiri@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
